Member Info for JoeyDiamond

The RNS today I thought was disappointing and was I suspect released to try and hold the SP up after the demerger.

I worry that there is no information on the trial design (that I could find) and the RNS suggests they will be targeting later stage patients with severe disease. I hoped they would target the earlier stage however without more trial design info can't be sure.

I sold my TILs this morning and with some of the cash have added a few here at 167.

If we get another drop in SP will probably make a further buy in. I think we are going to get alot of news this month.

Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil

I have been searching for information on the trial design but no luck. Nothing on TILs website nor on https://clinicaltrials.gov/ct2/home

Anyone got a link to further trial info? Thx

Thanks EwanRef, we have seen a number of government responses on this board but yours is the most detailed so far. It looks like the government department has greenlighted more information to be shared with the public. Good signs!

Thanks Helen3 for posting that info. It was a question I was asking myself how many people in the P2 were on score 4 but somehow I missed that info!

3 = Hospitalised - no oxygen therapy, Placebo: 19 (38%), SNG001: 11 (23%)
4 = Oxygen by mask, or nasal prongs, Placebo: 28 (56%), SNG001: 36 (75%)

My worry was we were going to have majority of patients using SNG001 at score 3 (non oxygen) meaning the new P3 trial design would be much tougher and repeat results less likely.

However what we can see from those results is more patients were given the placebo at the earlier stage 3 of the disease (no oxygen) than SNG001.

Only 23% at score 3 were given SNG001 which means the results are better than I first thought when relating to the new P3 design.

The WHO ord scale 4 in P3 was one of my big fears/risks and im a very happy holder tonight.

https://twitter.com/Synairgenplc/status/1322201041425833984

Yesterday CEO Richard Marsden spoke at BIO Europe digital on a panel discussing COVID-19 therapeutics, and on progressing Synairgen’s #SNG001 drug into later stage trials. Access BIO’s #COVID19 therapeutic development tracker here:

and Eric Topol now tweeting about it

https://twitter.com/EricTopol/status/1322168974973362176
#
A disappointing replication: monoclonal antibodies to #SARSCoV2 don't provide benefit to hospitalized patients w/ moderate-severe illness. The need to treat #COVID19 early or preventatively
https://investor.regeneron.com/news-releases/news-release-details/regn-cov2-independent-data-monitoring-committee-recommends/ like Lilly futility Phase 2 trial decision

So like Eli Lilly MABs they have been having issues in patients scoring 5 or more in WHO ordinal scale (5-8 classed as severe disease) and they have been told to change their trials to be done on people at a much earlier stage of the disease.

Now they are to be targeted at patients at either WHO score 3/4 (mild/moderate disease). For reference Synairgens P3 trial will be used on patients at the score of 4 on the WHO ordinal scale.

https://investor.regeneron.com/news-releases/news-release-details/regn-cov2-independent-data-monitoring-committee-recommends

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody ****tail treatment trials for COVID-19 that the current hospitalized patient trial be modified. Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommends further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold pending collection and analysis of further data on patients already enrolled. The IDMC also recommends continuing enrollment of hospitalized patients requiring either no or low-flow oxygen as the risk/benefit remains acceptable in these cohorts. Finally, the IDMC recommends continuation of the outpatient trial without modification.

For further updates my guess is we get news in the next couple of weeks into November.

17/09/2020 was when the temporary AIM suspension occured

What we know from RNS-
WeShop plans to launch its proprietary, globally scalable e-commerce platform in Q4 of this year, having established strong links with key partners. WeShop recently announced it had raised £9 million which will help ensure the company's success as it seeks to capitalise on the rapid growth in e-commerce, which is only being accelerated by the global pandemic.

In addition, and as announced on 17 September 2020, the Company has agreed terms for the acquisition of BrandShield in a share for share offer, subject to the finalisation and signing of a share purchase agreement and a placing agreement in relation to a fundraising. The Directors believe that BrandShield is a very exciting value proposition and will benefit greatly from a public listing in order to execute its development roadmap to enable it to win more customers. BrandShield's product is now highly developed and it is aiming to significantly increase sales & marketing activity to capitalise on the rapid growth in its industry, in part caused by an acceleration in online criminal activity caused by COVID-19.

RorkesDrift my thoughts exactly. Im fully expecting a big drop in the SP although I do hope im wrong and the majority of the board are correct :)

As you mention the overall value of Accustem + TILs in time will be much more than the current TILS SP so its a good hold.

Here is some old news regarding the help Synairgen received from NIHR during our phase 2 trial and why their help was very welcome.

https://oxfordbrc.nihr.ac.uk/new-treatment-reduces-covid-19-patients-needing-intensive-care/

In particular if you look here you can see the various locations/names of the leading people/locations who were likely involved.

Respiratory Translational Research Collaboration Academic Centres
https://www.nihr.ac.uk/partners-and-industry/industry/collaborate-with-us/respiratory-trc.htm

If you check the Phase 2 trial many of the locations used match up to whats listed here.
Southamptons entry is Professor Ratko Djukanovic.

It looks like we will have good support and will be interesting to keep an eye out on these websites.

This news has already been included in an RNS, as typical Synairgen style it is tucked away amongst lots of other info.

From Placing and Open Offer RNS -

'On 14 October 2020 the Company was informed by the National Institute for Health Research (NIHR) that the Phase III trial has been badged in the UK as Urgent Public Health and will be recognised as a National Priority study'

Yes its about vaccines but a question like 'What happens in the event vaccines are delayed/failure do we have any other plans/theraputics?' etc

https://twitter.com/NIH/status/1321811036652019718

Join us TODAY (10/29) at 12:00 pm ET live on #NIH’s Facebook and Twitter profiles to hear @NIHDirector
Dr. Francis Collins and @NIAIDNews
Director Dr. Anthony Fauci answer your questions about #COVID19 vaccine research.

Another chance for questions :)

No definative timeline yet. RM has stated he hopes for November start date and 2 months for data.

https://twitter.com/BNODesk/status/1321221403681693696

French media reports that a 4-week, nationwide lockdown is now the government's preferred option. "If we can save Christmas, let's consider ourselves lucky," one source told Europe 1

In a nutshell the vaccine gamble has failed as many predicted. Not many people will commit to having a vaccine every 3 months, especially one thats been rushed through and has no long term testing.

Therapies and mass testing/tracing are the way out of Covid as proven by many countries like New Zealand, South Korea, Japan, Thailand, Taiwan etc

The article was posted today on Avactas twitter feed so would suggest the AS interview was yesterday or this morning.

https://twitter.com/avacta